INTRODUCTION
The last decade has seen a dramatic increase in the use of genomic assays in routine clinical practice for patients with early-stage breast cancer. These genomic assays differ in the technological platforms, development, analytical and clinical validation as well as the gene sets that are included in the algorithm. [8] We hypothesized that the 21-gene assay and the Prosigna assay also stratify patients differently. To test this hypothesis, we performed a prospectively designed comparison between these assays using the same formalin-fixed, paraffin-embedded (FFPE) tumor samples.
METHODS

Study Design
The The study was reviewed and approved by an institutional review board and was granted a waiver for obtaining patient consent since there were no patient outcomes included in the analysis. All samples were de-identified for patient specific information. was used for the analysis.
Patients and Samples
Consecutive
RESULTS
Patients and Samples
A total of 70 consecutive samples were obtained from Marin Medical Laboratories. Samples from 18 patients were excluded: four were ER-negative, six were node-positive, five were premenopausal, and three yielded insufficient tumor RNA for the 21-gene assay. The number of samples included in the final analysis cohort was 52.
More than half of the samples (55.8%) were from patients aged C70 years. The majority of tumors were invasive ductal carcinoma (73.1%), B2 cm in size (78.9%), and grade 1 or 2 (90.4%; Table 1 ).
Distribution of Recurrence Score and Prosigna Results
The distribution of the Recurrence Score and the Prosigna results exhibited marked differences as there were more patients classified as low risk and fewer patients classified as intermediate or high risk by the Recurrence Score result compared to the Prosigna result (Fig. 1) (Fig. 1a, b) .
Comparison of Risk Scores
Overall agreement for risk classification based on the Recurrence Score and the Prosigna score results was 53.8% (Table 2) . Thirty-seven Prosigna assay, the other two were low and intermediate (Fig. 1c) .
Quantitative ER Expression
Evaluation of quantitative ER expression (by RT-PCR) showed a wide range of expression within each Prosigna score risk group (Fig. 2 Score results (Fig. 3) . Specifically, among the 38 luminal A samples, 1 (2.6%) had a high 
DISCUSSION
The current analysis, the first prospectively designed comparison between the Recurrence showed an agreement in risk group assignment (in node-negative patients; n = 739) of 58%, which is similar to the 53% observed here. In (12) [17]. Notably, in the Dowsett et al. [17] study, the ROR assay was performed on residual RNA extracted by Genomic Health in an earlier study (i.e., samples were microdissected and the RNA was extracted using Genomic Health proprietary methods), which may be relevant, since RNA extraction methods have been shown to impact gene expression analysis [24] .
Indeed, the results in the validation study conducted in TransATAC were substantially different from those reported for the validation study conducted in the ABCSG-8
trial with the risk of recurrence being approximately twofold higher in patients with a high and intermediate ROR scores [16, 17] ; possibly due to different RNA extraction methods, differences in patient populations, or both. Furthermore, in the Dowsett et al. [17] analysis, the cut points for the Recurrence Score risk groups were not based on the validated values defining the Recurrence Score risk groups (\18, 18-30, C31), but rather percentage risk based on the ROR categories (\10%, 10-20%, [20%).
Our results are also consistent with findings from previous studies comparing Recurrence Score-based risk assessments with risk assessment based on other assays, including the 70-gene assay, the five-antibody assay, and the 12-gene assay [20] [21] [22] , as well as with recent findings from the prospective OPTIMA pilot feasibility study which compared risk assignments between the Recurrence Score assay, the 70-gene assay, the Prosigna assay, IHC4, and IHC4 AQUA Ò (Genoptix, Carlsbad, CA, USA) as part of the feasibility of using a genomic profile assay for treatment decisions [25] . These studies revealed consistent differences in risk classification between the assays. Most notably that the Recurrence Score assay consistently classifies fewer patients as high risk. These differences may be due to the different platforms (e.g., array vs. RT-PCR), different genes included in the assays, and differences in clinical validation (e.g., using
legacy trials with long-term follow-up vs. convenience samples where patients were not treated uniformly) [1] [2] [3] [4] [5] [6] [16] [17] [18] . To date, the Recurrence Score assay is the only one shown to predict the likelihood of chemotherapy benefit (i.e., which patients are likely to benefit from adding chemotherapy to endocrine therapy and which are unlikely to derive benefit) [2, 4] .
Our study was able to identify patients with high Prosigna score results and low Recurrence Score results. Based on the Recurrence Score validation studies [2, 4] , such patients are likely to have little to no chemotherapy benefit. Furthermore, in our study, these patients had high ER expression levels, and thus were likely to derive substantial benefit from endocrine therapy alone which is of clinical relevance since the Prosigna assay was developed in untreated patients.
Of note, the 5-year outcomes for the study arm of 1626 ER-positive, node-negative patients with a Recurrence Score result \11 enrolled in the TAILORx study (the largest prospective adjuvant trial to date) were recently published in the New England Journal of Medicine and confirmed the very low distant recurrence risk for patients treated with endocrine therapy alone (rate of freedom from distant recurrence at 5 years: 99.3%) [7] . This 5-year distant recurrence rate in this contemporary cohort is even lower than expected based on the prior experience reported in the validation studies [26] . Furthermore, with a recurrence rate so low, it is certain that patients with a low Recurrence Score result will not derive additional benefit from the addition of chemotherapy.
Additional clinical relevance of our findings pertains to the use of intrinsic subtypes (luminal A or B) to assess recurrence risk and make treatment decisions. To date, there has not been a standardized method to determine luminal subtype, aside from the original PAM50 microarray. In addition, while the luminal subtypes differ prognostically, there is no evidence that luminal subtyping is predictive of chemotherapy benefit. In our study, 83% of the luminal B patients had low Recurrence Score results, and are therefore likely to have little to no benefit from chemotherapy. Furthermore, in our study, these patients also had high ER expression, and thus, are expected to benefit substantially from endocrine therapy alone, as noted above.
While this is the first truly blinded head-to-head comparison of the Recurrence Score and Prosigna assays, the study does have some limitations. The study was designed to compare the Recurrence Score and Prosigna assays, focusing solely on risk estimates. Discerning the impact of the differences in risk stratification on treatment decisions and clinical outcomes was beyond the scope of the current study (as outcome data were not available). In addition, it is a single-center study with a relatively small sample size.
Consequently, subgroup analysis exploring the discordance between the assays in subgroups of patients based on tumor/patient characteristics such as age, grade, and tumor size was not possible.
CONCLUSIONS
The consistency of the results from this comparison of the Recurrence Score and Prosigna assays and prior studies showing that different assays vary substantially in risk assignation, indicates that genomic assays cannot be used interchangeably. In particular, since the correlation of the Recurrence Score results (which is the only assay validated to predict chemotherapy benefit) and the results of other assays is poor-to-modest, it cannot be assumed that the other assays are also predictive of chemotherapy benefit. As new assays become available, it will be critically important to understand the differences between the assays to comprehend the implications for clinical practice. 
